CN Patent

CN105640878A — 一种坦西莫司注射用浓溶液及其制备方法

Assigned to Suzhou University · Expires 2016-06-08 · 10y expired

What this patent protects

本发明属于医药制剂技术领域，具体涉及一种坦西莫司注射用浓溶液及其制备方法，主要由活性成分、丙二醇、尼泊金丙酯、葡甲胺、无水柠檬酸和无水乙醇组成。本发明制剂，便于生产中过滤和灌装，减少了坦西莫司注射用浓溶液生产时间，提高了产品的无菌保障水平；本发明制得的坦西莫司注射用浓溶液可以最大程度的将药液灌装，避免了由于丙二醇浓度过高引起生产中药液残留过多而使产品收率下降，同时在临床应用中便于抽取，避免了由于药液在包装容器中残留，引起药品治疗量的不足。

USPTO Abstract

本发明属于医药制剂技术领域，具体涉及一种坦西莫司注射用浓溶液及其制备方法，主要由活性成分、丙二醇、尼泊金丙酯、葡甲胺、无水柠檬酸和无水乙醇组成。本发明制剂，便于生产中过滤和灌装，减少了坦西莫司注射用浓溶液生产时间，提高了产品的无菌保障水平；本发明制得的坦西莫司注射用浓溶液可以最大程度的将药液灌装，避免了由于丙二醇浓度过高引起生产中药液残留过多而使产品收率下降，同时在临床应用中便于抽取，避免了由于药液在包装容器中残留，引起药品治疗量的不足。

Drugs covered by this patent

Patent Metadata

Patent number
CN105640878A
Jurisdiction
CN
Classification
—
Expires
2016-06-08
Drug substance claim
No
Drug product claim
No
Assignee
Suzhou University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.